Literature DB >> 26531705

Monitoring oligoclonal immunoglobulins in cerebral spinal fluid using microLC-ESI-Q-TOF mass spectrometry.

David R Barnidge1, Mindy C Kohlhagen2, Sunny Zheng2, Maria A V Willrich2, Jerry A Katzmann2, Sean J Pittock3, David L Murray2.   

Abstract

Our group has previously shown that mass spectrometry can be used to detect and quantify monoclonal and polyclonal immunoglobulin light chains in serum and urine from patients with monoclonal gammopathies and polyclonal hypergammaglobinemia. Here we demonstrate the use of the methodology, also referred to as monoclonal immunoglobulin Rapid Accurate Mass Measurement\with (miRAMM), to detect oligoclonal immunoglobulins above the polyclonal background in cerebral spinal fluid (CSF) and serum. We compared the findings for 56 paired CSF and serum samples analyzed by IgG IEF and miRAMM. The two methods were in agreement with 54 samples having concordant results (22 positive and 34 negative) and 2 that were positive by IgG IEF but negative by miRAMM. In addition to identifying oligoclonal immunoglobulins, miRAMM can be used to quantify and isotype each specific monoclonal immunoglobulin in CSF. This methodology has the potential to transform the way the inflammatory response is monitored in the CNS compartment.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CSF; Mass spectrometry; Monoclonal immunoglobulins; Monoclonal light chains; Multiple sclerosis; Oligoclonal banding

Mesh:

Substances:

Year:  2015        PMID: 26531705     DOI: 10.1016/j.jneuroim.2015.09.011

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  1 in total

1.  Analysis of Monoclonal Antibodies in Human Serum as a Model for Clinical Monoclonal Gammopathy by Use of 21 Tesla FT-ICR Top-Down and Middle-Down MS/MS.

Authors:  Lidong He; Lissa C Anderson; David R Barnidge; David L Murray; Christopher L Hendrickson; Alan G Marshall
Journal:  J Am Soc Mass Spectrom       Date:  2017-02-28       Impact factor: 3.109

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.